USC.edu
Are you a Patient?

Alan S. Wayne, MD

Chair, Department of Pediatrics Professor of Pediatrics and Medicine, Keck School of Medicine of USC

Pediatrician-in-Chief and Senior Vice President of Academic Affairs

Pasadena Guild Chair Children's Hospital Los Angeles

Image of Alan S. Wayne, MD
Websites
Is this your profile? Click to edit
Phone +1 323 361 8670
Email awayne@chla.usc.edu
CTSI Profile

Overview

Alan S. Wayne, MD serves as Chair of the Department of Pediatrics at the Keck School of Medicine of USC and Senior Vice President of Academic Affairs and Pediatrician-in-Chief at Children’s Hospital Los Angeles (CHLA). Dr. Wayne is Professor of Pediatrics and Medicine at the Keck School of Medicine of USC. In these roles, Dr. Wayne oversees the Department’s clinical care delivery, medical education, and research programs, and leads the departmental strategy, faculty affairs, and budget management in the context of the missions of USC and CHLA.

Dr. Wayne’s primary research efforts are directed toward the development of new treatment approaches for leukemias and lymphomas, with a focus on targeted, immune-based, and cellular therapies. He is the Medical Director of the Therapeutic Advances in Childhood Leukemia/Lymphoma (TACL) Consortium, a multinational clinical trials group headquartered at CHLA. He has an ongoing leadership role in the development of genetically modified chimeric antigen receptor (CAR) T-cells for childhood hematologic malignancies. Additionally, he plays a leadership role in international efforts in the area of post-transplant relapse of hematologic malignancies, the primary aim of which is to study the biology, prevention, and treatment of relapse after hematopoietic stem cell transplantation.

Board-certified in pediatric hematology-oncology, Dr. Wayne attended the Honors Program in Medical Education obtaining his BS and MD degrees from Northwestern University. He conducted internship, residency, and chief residency in pediatrics at Boston Children’s Hospital followed by pediatric hematology-oncology fellowship at Boston Children’s Hospital and the Dana-Farber Cancer Institute.

Publications

  • Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium Cancers (Basel). 2024 Jan 24; 16(3). . View in PubMed
  • Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia Haematologica. 2023 03 01; 108(3):747-760. . View in PubMed
  • Real-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium Pediatr Blood Cancer. 2022 10; 69(10):e29812. . View in PubMed
  • Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium Am J Hematol. 2022 05; 97(5):613-622. . View in PubMed
  • Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001) Haematologica. 2022 10 01; 107(10):2295-2303. . View in PubMed
  • In vitro and in vivo effects of AVA4746, a novel competitive antagonist of the ligand binding of VLA-4, in B-cell acute lymphoblastic leukemia Exp Ther Med. 2022 Jan; 23(1):47. . View in PubMed
  • Targeting HLA-DR loss in hematologic malignancies with an inhibitory chimeric antigen receptor Mol Ther. 2022 03 02; 30(3):1215-1226. . View in PubMed
  • Modified Manufacturing Process Modulates CD19CAR T-cell Engraftment Fitness and Leukemia-Free Survival in Pediatric and Young Adult Subjects Cancer Immunol Res. 2022 07 01; 10(7):856-870. . View in PubMed
  • Immunogenicity of CAR T cells in cancer therapy Nat Rev Clin Oncol. 2021 06; 18(6):379-393. . View in PubMed
  • Fatal capillary leak syndrome in a child with acute lymphoblastic leukemia treated with moxetumomab pasudotox for pre-transplant minimal residual disease reduction Pediatr Blood Cancer. 2021 01; 68(1):e28574. . View in PubMed
  • Managing therapy-associated neurotoxicity in children with ALL Hematology Am Soc Hematol Educ Program. 2021 12 10; 2021(1):376-383. . View in PubMed
  • A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation Blood. 2021 02 18; 137(7):983-993. . View in PubMed
  • Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia Pediatr Blood Cancer. 2020 05; 67(5):e28112. . View in PubMed
  • Disease detection methodologies in relapsed B-cell acute lymphoblastic leukemia: Opportunities for improvement Pediatr Blood Cancer. 2020 04; 67(4):e28149. . View in PubMed
  • CAR T-cell product performance in haematological malignancies before and after marketing authorisation Lancet Oncol. 2020 02; 21(2):e104-e116. . View in PubMed
  • Integrin a6 mediates the drug resistance of acute lymphoblastic B-cell leukemia Blood. 2020 07 09; 136(2):210-223. . View in PubMed
  • Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study Clin Cancer Res. 2020 05 15; 26(10):2297-2307. . View in PubMed
  • Extracellular vesicles derived from natural killer cells use multiple cytotoxic proteins and killing mechanisms to target cancer cells J Extracell Vesicles. 2019; 8(1):1588538. . View in PubMed
  • The American Society of Pediatric Hematology/Oncology workforce assessment: Part 2-Implications for fellowship training Pediatr Blood Cancer. 2018 Feb; 65(2). . View in PubMed
  • The American Society of Pediatric Hematology/Oncology workforce assessment: Part 1-Current state of the workforce Pediatr Blood Cancer. 2018 Feb; 65(2). . View in PubMed
  • Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study Leukemia. 2018 11; 32(11):2316-2325. . View in PubMed
  • Myeloid lineage switch following chimeric antigen receptor T-cell therapy in a patient with TCF3-ZNF384 fusion-positive B-lymphoblastic leukemia Pediatr Blood Cancer. 2018 09; 65(9):e27265. . View in PubMed
  • Third International workshop on the biology, prevention, and treatment of relapse after stem cell transplantation Bone Marrow Transplant. 2018 01; 53(1):1-2. . View in PubMed
  • A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium Blood. 2018 03 08; 131(10):1145-1148. . View in PubMed
  • Domain II of Pseudomonas Exotoxin Is Critical for Efficacy of Bolus Doses in a Xenograft Model of Acute Lymphoblastic Leukemia Toxins (Basel). 2018 05 21; 10(5). . View in PubMed
  • 5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox Proc Natl Acad Sci U S A. 2018 02 20; 115(8):E1867-E1875. . View in PubMed
  • The PI3Kd Inhibitor Idelalisib Inhibits Homing in an in Vitro and in Vivo Model of B ALL Cancers (Basel). 2017 Sep 10; 9(9). . View in PubMed
  • Investigating the biology of relapsed acute leukemia: Proceedings of the Therapeutic Advances for Childhood Leukemia & Lymphoma (TACL) Consortium Biology Working Group Pediatr Hematol Oncol. 2017 Sep – Oct; 34(6-7):355-364. . View in PubMed
  • Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL): Overview and introduction to the proceedings of the 2016 TACL investigator meeting Pediatr Hematol Oncol. 2017 Sep – Oct; 34(6-7):349-354. . View in PubMed
  • Biological roles and potential applications of immune cell-derived extracellular vesicles J Extracell Vesicles. 2017; 6(1):1400370. . View in PubMed
  • Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia Blood. 2017 10 05; 130(14):1620-1627. . View in PubMed
  • Large-scale isolation and cytotoxicity of extracellular vesicles derived from activated human natural killer cells J Extracell Vesicles. 2017; 6(1):1294368. . View in PubMed
  • Cells to prevent/treat relapse following allogeneic stem cell transplantation Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):708-715. . View in PubMed
  • Wide Variability in the Time Required for Immunotoxins to Kill B Lineage Acute Lymphoblastic Leukemia Cells: Implications for Trial Design Clin Cancer Res. 2016 Oct 01; 22(19):4913-4922. . View in PubMed
  • Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®): Results From a Phase I Study in Children, Adolescents, and Young Adults With Refractory Solid Tumors or Leukemias Pediatr Blood Cancer. 2016 Jun; 63(6):997-1005. . View in PubMed
  • Plasma and cerebrospinal fluid pharmacokinetics of vincristine and vincristine sulfate liposomes injection (VSLI, marqibo®) after intravenous administration in Non-human primates Invest New Drugs. 2016 Feb; 34(1):61-5. . View in PubMed
  • Induction of Immune Response after Allogeneic Wilms’ Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse Biol Blood Marrow Transplant. 2016 12; 22(12):2149-2154. . View in PubMed
  • Treatment-related adverse events associated with a modified UK ALLR3 induction chemotherapy backbone for childhood relapsed/refractory acute lymphoblastic leukemia Pediatr Blood Cancer. 2016 11; 63(11):1943-8. . View in PubMed
  • Bortezomib, Dexamethasone, Mitoxantrone, and Vinorelbine (BDMV): An Active Reinduction Regimen for Children With Relapsed Acute Lymphoblastic Leukemia and Asparaginase Intolerance J Pediatr Hematol Oncol. 2016 07; 38(5):345-9. . View in PubMed
  • Protein Kinase Inhibitor H89 Enhances the Activity of Pseudomonas Exotoxin A-Based Immunotoxins Mol Cancer Ther. 2016 05; 15(5):1053-62. . View in PubMed
  • Improving access to novel agents for childhood leukemia Cancer. 2015 Jun 15; 121(12):1927-36. . View in PubMed
  • Characterization of CD22 expression in acute lymphoblastic leukemia Pediatr Blood Cancer. 2015 Jun; 62(6):964-9. . View in PubMed
  • Is another antibody conjugate against ALL needed? Lancet Haematol. 2015 Mar; 2(3):e87-8.. View in PubMed
  • Abnormal bone marrow histopathology in paediatric mastocytosis Br J Haematol. 2015 Mar; 168(6):865-73. . View in PubMed
  • T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial Lancet. 2015 Feb 07; 385(9967):517-528. . View in PubMed
  • Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation Blood. 2015 Jan 29; 125(5):784-92. . View in PubMed
  • Children as hematopoietic cell donors in research: when is it approvable? Bone Marrow Transplant. 2015 Jan; 50(1):15-9.. View in PubMed
  • New frontiers in pediatric Allo-SCT: novel approaches for children and adolescents with ALL Bone Marrow Transplant. 2014 Oct; 49(10):1259-65. . View in PubMed
  • Feasibility of treating post-transplantation minimal residual disease in children with acute leukemia Biol Blood Marrow Transplant. 2014 Jul; 20(7):1000-7. . View in PubMed
  • Factors predictive of relapse of acute leukemia in children after allogeneic hematopoietic cell transplantation Biol Blood Marrow Transplant. 2014 Jul; 20(7):1033-9. . View in PubMed
  • Immunotoxins for leukemia Blood. 2014 Apr 17; 123(16):2470-7. . View in PubMed
  • Proceedings from the National Cancer Institute’s Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part IIIPrevention and treatment of relapse after allogeneic transplantation. Biol Blood Marrow Transplant. 2014 Jan; 20(1):4-13. . View in PubMed
  • Proceedings from the National Cancer Institute’s Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part IIAutologous Transplantation-novel agents and immunomodulatory strategies. Biol Blood Marrow Transplant. 2013 Dec; 19(12):1661-9. . View in PubMed
  • Methylation of the DPH1 promoter causes immunotoxin resistance in acute lymphoblastic leukemia cell line KOPN-8 Leuk Res. 2013 Nov; 37(11):1551-6. . View in PubMed
  • Proceedings from the National Cancer Institute’s Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part IBiology of relapse after transplantation. Biol Blood Marrow Transplant. 2013 Nov; 19(11):1537-45. . View in PubMed
  • Proceedings from the National Cancer Institute’s Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: introduction Biol Blood Marrow Transplant. 2013 Nov; 19(11):1534-6. . View in PubMed
  • Simplified process for the production of anti-CD19-CAR-engineered T cells Cytotherapy. 2013 Nov; 15(11):1406-15. . View in PubMed
  • A modified form of diphthamide causes immunotoxin resistance in a lymphoma cell line with a deletion of the WDR85 gene J Biol Chem. 2013 Apr 26; 288(17):12305-12. . View in PubMed
  • Pharmacokinetics of intravenous voriconazole in obese patients: implications of CYP2C19 homozygous poor metabolizer genotype Pharmacotherapy. 2013 Mar; 33(3):e19-22. . View in PubMed
  • Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia Blood. 2013 Feb 14; 121(7):1165-74. . View in PubMed
  • Immunotherapy for pediatric leukemia Front Oncol. 2013; 3:166. . View in PubMed
  • Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia J Clin Oncol. 2012 Nov 01; 30(31):3876-83. . View in PubMed
  • Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans Blood. 2012 Nov 01; 120(18):3635-46. . View in PubMed
  • Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challenges Am J Hematol. 2012 Sep; 87(9):916-22. . View in PubMed
  • Pretransplant MRD: the light is yellow, not red Blood. 2012 Jul 12; 120(2):244-6. . View in PubMed
  • Reduced-intensity allogeneic stem cell transplantation in children and young adults with ultrahigh-risk pediatric sarcomas Biol Blood Marrow Transplant. 2012 May; 18(5):698-707. . View in PubMed
  • Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy Proc Natl Acad Sci U S A. 2012 May 01; 109(18):6898-903. . View in PubMed
  • Multicentric dermatofibrosarcoma protuberans in patients with adenosine deaminase-deficient severe combined immune deficiencyJ Allergy Clin Immunol. 2012 Mar; 129(3):762-769. e1. . View in PubMed
  • Bone marrow homing and engraftment of human hematopoietic stem and progenitor cells is mediated by a polarized membrane domain Blood. 2012 Feb 23; 119(8):1848-55. . View in PubMed
  • Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations Clin Lymphoma Myeloma Leuk. 2012 Feb; 12(1):20-5. . View in PubMed
  • Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies PLoS One. 2012; 7(12):e52655. . View in PubMed
  • Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates Cancer Res. 2011 Oct 15; 71(20):6300-9. . View in PubMed
  • Myeloid dysplasia and bone marrow hypocellularity in adenosine deaminase-deficient severe combined immune deficiency Blood. 2011 Sep 08; 118(10):2688-94. . View in PubMed
  • Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States Blood. 2011 Jun 02; 117(22):5835-49. . View in PubMed
  • Therapeutic antibiotic use patterns in dogs: observations from a veterinary teaching hospital J Small Anim Pract. 2011 Jun; 52(6):310-8. . View in PubMed
  • Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737 Leuk Lymphoma. 2011 Jun; 52 Suppl 2:79-81. . View in PubMed
  • Long-term remission in a child with refractory EBV(+) hydroa vacciniforme-like T-cell lymphoma through sequential matched EBV(+)-related allogeneic hematopoietic SCT followed by donor-derived EBV-specific cytotoxic T-lymphocyte immunotherapy Bone Marrow Transplant. 2011 May; 46(5):759-61. . View in PubMed
  • National Cancer Institute’s First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee Biol Blood Marrow Transplant. 2011 Apr; 17(4):443-54. . View in PubMed
  • Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells J Immunother. 2011 Mar; 34(2):187-95. . View in PubMed
  • Variables affecting the quantitation of CD22 in neoplastic B cells Cytometry B Clin Cytom. 2011 Mar; 80(2):83-90. . View in PubMed
  • High frequencies of leukemia stem cells in poor-outcome childhood precursor-B acute lymphoblastic leukemias Leukemia. 2010 Nov; 24(11):1859-66. . View in PubMed
  • Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications Haematologica. 2010 Nov; 95(11):1873-9. . View in PubMed
  • NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation Biol Blood Marrow Transplant. 2010 Nov; 16(11):1467-503. . View in PubMed
  • NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantationpart II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies. Biol Blood Marrow Transplant. 2010 Oct; 16(10):1325-46. . View in PubMed
  • NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell TransplantationPart I: Methods, acute leukemias, and myelodysplastic syndromes. Biol Blood Marrow Transplant. 2010 Sep; 16(9):1187-211. . View in PubMed
  • Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia Br J Haematol. 2010 Aug; 150(3):352-8. . View in PubMed
  • Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation Biol Blood Marrow Transplant. 2010 May; 16(5):563-4. . View in PubMed
  • The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma Blood. 2010 Apr 15; 115(15):3017-24. . View in PubMed
  • Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial Clin Cancer Res. 2010 Mar 15; 16(6):1894-903. . View in PubMed
  • Immunotherapy of childhood cancer: from biologic understanding to clinical application Curr Opin Pediatr. 2010 Feb; 22(1):2-11. . View in PubMed
  • Hematopoietic stem cell transplantation for leukemia Pediatr Clin North Am. 2010 Feb; 57(1):1-25. . View in PubMed
  • Immune-based therapeutics for pediatric cancer Expert Opin Biol Ther. 2010 Feb; 10(2):163-78. . View in PubMed
  • Juvenile xanthogranuloma in a child with previously unsuspected neurofibromatosis type 1 and juvenile myelomonocytic leukemia Pediatr Blood Cancer. 2010 Jan; 54(1):173-5. . View in PubMed
  • Extracorporeal photo-apheresis for the treatment of steroid-resistant graft versus host disease Transfus Apher Sci. 2009 Dec; 41(3):209-16. . View in PubMed
  • Application of immunotherapy in pediatric leukemia Curr Hematol Malig Rep. 2009 Jul; 4(3):159-66. . View in PubMed
  • Progress in the curative treatment of childhood hematologic malignancies J Natl Cancer Inst. 2008 Sep 17; 100(18):1271-3. . View in PubMed
  • Mass spectrometric quantification of asparagine synthetase in circulating leukemia cells from acute lymphoblastic leukemia patients J Proteomics. 2008 Apr 30; 71(1):61-70. . View in PubMed
  • Sibling stem cell donor experiences at a single institution Psychooncology. 2008 Mar; 17(3):304-7. . View in PubMed
  • Triad of severe abdominal pain, inappropriate antidiuretic hormone secretion, and disseminated varicella-zoster virus infection preceding cutaneous manifestations after hematopoietic stem cell transplantation: utility of PCR for early recognition and therapy Pediatr Infect Dis J. 2008 Mar; 27(3):265-8. . View in PubMed
  • Vulvovaginal chronic graft-versus-host disease with allogeneic hematopoietic stem cell transplantation Obstet Gynecol. 2007 Nov; 110(5):1041-9. . View in PubMed
  • Thromboembolic events in children and young adults with pediatric sarcoma J Clin Oncol. 2007 Apr 20; 25(12):1519-24. . View in PubMed
  • The transfusion of neutrophil-specific antibodies causes leukopenia and a broad spectrum of pulmonary reactions Transfusion. 2007 Mar; 47(3):545-50. . View in PubMed
  • Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma Leukemia. 2007 Jan; 21(1):169-74. . View in PubMed
  • Hematopoietic stem cell donation in children: a review of the sibling donor experience J Psychosoc Oncol. 2007; 25(1):45-66. . View in PubMed
  • Psychotropic medication use in pediatric patients with cancer Arch Pediatr Adolesc Med. 2006 Aug; 160(8):818-22. . View in PubMed
  • Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: VAncillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant. 2006 Apr; 12(4):375-96. . View in PubMed
  • Unique abnormalities of CD4(+) and CD8(+) central memory cells associated with chronic graft-versus-host disease improve after extracorporeal photopheresis Biol Blood Marrow Transplant. 2006 Jan; 12(1 Suppl 2):22-30. . View in PubMed
  • Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database J Clin Oncol. 2005 Jul 20; 23(21):4735-41. . View in PubMed
  • Two novel CHS1 (LYST) mutations: clinical correlations in an infant with Chediak-Higashi syndrome Mol Genet Metab. 2005 Jun; 85(2):125-32. . View in PubMed
  • Autologous hematopoietic stem-cell transplantation for children with acute myeloid leukemia in first or second complete remission: a prognostic factor analysis J Clin Oncol. 2004 Sep 15; 22(18):3798-804. . View in PubMed
  • Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease Bone Marrow Transplant. 2004 May; 33(10):1031-5. . View in PubMed
  • Pediatric large-volume leukapheresis: a single institution experience with heparin versus citrate-based anticoagulant regimens Transfusion. 2004 Feb; 44(2):229-38. . View in PubMed
  • Allogeneic hematopoietic stem cell transplantation for myeloproliferative disorders and myelodysplastic syndromes Hematol Oncol Clin North Am. 2003 Oct; 17(5):1243-60. . View in PubMed
  • Catastrophic failures of freezing bags for cellular therapy products: description, cause, and consequences Cytotherapy. 2002; 4(6):539-49. . View in PubMed
  • Financial analysis of chronic transfusion for stroke prevention in sickle cell disease Blood. 2000 Oct 01; 96(7):2369-72. . View in PubMed
  • Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim reportMulticenter investigation of bone marrow transplantation for sickle cell disease. Blood. 2000 Mar 15; 95(6):1918-24. . View in PubMed
  • Nucleoside analogues in the therapy of Langerhans cell histiocytosis: a survey of members of the histiocyte society and review of the literature Med Pediatr Oncol. 1999 Nov; 33(5):476-81. . View in PubMed
  • Collaborative multicenter investigation of marrow transplantation for sickle cell disease: current results and future directions Biol Blood Marrow Transplant. 1997 Dec; 3(6):310-5. . View in PubMed
  • Barriers to bone marrow transplantation for sickle cell anemia Biol Blood Marrow Transplant. 1996 May; 2(2):100-4. . View in PubMed
  • Recipient T-cell immune reconstitution in X-linked SCID after haploidentical maternal bone marrow transplant Ann N Y Acad Sci. 1995 Dec 29; 770:376-7. . View in PubMed
  • Clonality in juvenile chronic myelogenous leukemia Blood. 1995 Jan 01; 85(1):21-30. . View in PubMed
  • Total hip arthroplasty in beta-thalassemiaCase report and review of the literature. Clin Orthop Relat Res. 1993 Sep; (294):149-54. . View in PubMed
  • Transfusion management of sickle cell disease Blood. 1993 Mar 01; 81(5):1109-23. . View in PubMed
  • Perioperative management for cholecystectomy in sickle cell disease J Pediatr Surg. 1993 Jan; 28(1):72-5. . View in PubMed
  • Stage III neuroblastoma over 1 year of age at diagnosis: improved survival with intensive multimodality therapy including multiple alkylating agents J Clin Oncol. 1993 Jan; 11(1):84-90. . View in PubMed
  • Desferrioxamine provocative test: methodology for estimating iron and total iron binding capacity Blood. 1990 Nov 15; 76(10):2162. . View in PubMed
  • Treatment of Cooley’s anemia: deferoxamine provocation test Blood. 1990 Nov 01; 76(9):1897. . View in PubMed
  • The evaluation of diagnostic tests for cancer; inhibition of serum alkaline phosphate by zinc ion; the Roche test Cancer Res. 1949 Nov; 9(11):681-3. . View in PubMed

Similar People